Pfizer Appears Slightly Ahead Of Moderna In COVID-19 Vaccine Race
Executive Summary
Neither has announced a firm timeline, and the difference between Pfizer's 'October' and Moderna's 'November' could be mere hours or a few weeks, but Pfizer, by dint of luck or experience, is now in a position to offer the more optimistic projection on when it will seek an EUA. Both firms release their Phase III trial protocols, which seem in line with US FDA guidance.
You may also be interested in...
COVID-19 Vaccine Race: With Moderna EUA, US FDA Finally Gets Some Bragging Rights
US FDA’s global first for Moderna’s vaccine gets a small mention as agency looks to pharmacovigilance, follow-up studies for both coronavirus inoculations that have now been authorized. Moderna's 18 December EUA comes after an even faster review than for Pfizer/BioNTech's vaccine.
COVID-19 Vaccines Blaze New Path In the History Of Vaccine Development
Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.
EUA For COVID-19 Vaccine Would Mean Fewer Patient-Years Of Follow-Up But More Pharmacovigilance
US FDA plans to leverage large safety surveillance databases to make up for the fact that a vaccine authorized for emergency use likely would have only one-quarter to one-half as much safety data follow-up as a typical vaccine licensed under a BLA, says CBER director Peter Marks.